Innate and adaptive immunity in inflammatory bowel disease

Autoimmunity Reviews

Volumn 13, Issue 1, 2014, Pages 3-10

  Geremia, Alessandra ^a   Biancheri, Paolo ^b   Allan, Philip ^a   Corazza, Gino R ^b   Di Sabatino, Antonio ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Autophagy; Cytokines; Innate lymphoid cell; T cell

Indexed keywords

GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; MUCIN 2; MUCIN 3; MUCIN 4; MUCIN 5B; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; POLYPEPTIDE ANTIBIOTIC AGENT; SECUKINUMAB;

ADAPTIVE IMMUNITY; ANKYLOSING SPONDYLITIS; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOPHAGY; BACTERIAL GROWTH; CELL DIFFERENTIATION; COLON MUCOSA; CROHN DISEASE; DENDRITIC CELL; DOWN REGULATION; ENTERITIS; GENETIC ASSOCIATION; HELPER CELL; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; INTESTINE CELL; INTESTINE EPITHELIUM; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; INTESTINE MUCOSA; LAMINA PROPRIA; LOSS OF FUNCTION MUTATION; LYMPHOID CELL; LYMPHOID TISSUE; MACROPHAGE; NONHUMAN; PANETH CELL; PATHOGENESIS; PHENOTYPE; POLYMERIZATION; PROTEIN EXPRESSION; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; TIGHT JUNCTION; ULCERATIVE COLITIS; UNFOLDED PROTEIN RESPONSE; UPREGULATION;

AUTOPHAGY; CD; CROHN'S DISEASE; CYTOKINES; DC; DENDRITIC CELL; GENOME-WIDE ASSOCIATION STUDIES; GWAS; IBD; IFN; IL; ILC; INFLAMMATORY BOWEL DISEASE; INKT; INNATE LYMPHOID CELL; INTERFERON; INTERLEUKIN; INVARIANT NATURAL KILLER T; MYD88; MYELOID DIFFERENTIATION PRIMARY RESPONSE GENE 88; NATURAL KILLER; NF; NK; NLR; NOD; NOD-LIKE RECEPTOR; NUCLEAR FACTOR; NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN; PAMP; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR; PRR; REGULATORY T CELL; T CELL; T HELPER CELL TYPE; TH; TLR; TNF; TOLL-LIKE RECEPTOR; TREG; TUMOR NECROSIS FACTOR; UC; ULCERATIVE COLITIS;

ADAPTIVE IMMUNITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84886951561     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.06.004     Document Type: Review

References (106)

1. Gill S.R., Pop M., Deboy R.T., et al. Metagenomic analysis of the human distal gut microbiome. Science 2006, 312:1355-1359.
2. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004, 126:1504-1517.
3. Bernstein C.N., Blanchard J.F., Rawsthorne P., Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001, 96:1116-1122.
4. Bernstein C.N., Wajda A., Blanchard J.F. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005, 129:827-836.
5. Baumgart D.C., Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007, 369:1641-1657.
6. Fuss I.J., Neurath M., Boirivant M., Klein J.S., de la Motte C., Strong S.A., et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996, 157:1261-1270.
7. Geremia A., Jewell D.P. The IL-23/IL-17 pathway in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2012, 6:223-237.
8. Van der Sluis M., De Koning B.A., De Bruijn A.C., Velcich A., Meijerink J.P., Van Goudoever J.B., et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006, 131:117-129.
9. Velcich A., Yang W., Heyer J., Fragale A., Nicholas C., Viani S., et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002, 295:1726-1729.
10. Buisine M.P., Desreumaux P., Debailleul V., Gambiez L., Geboes K., Ectors N., et al. Abnormalities in mucin gene expression in Crohn's disease. Inflamm Bowel Dis 1999, 5:24-32.
11. Salim S.Y., Soderholm J.D. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 2011, 17:362-381.
12. Barrett J.C., Lee J.C., Lees C.W., et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 2009, 41:1330-1334.
13. Anderson C.A., Boucher G., Lees C.W., et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011, 43:246-252.
14. Uehara A., Fujimoto Y., Fukase K., Takada H. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol Immunol 2007, 44:3100-3111.
15. Wehkamp J., Harder J., Weichenthal M., et al. Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2003, 9:215-223.
16. Wehkamp J., Salzman N.H., Porter E., et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 2005, 102:18129-18134.
17. Wehkamp J., Harder J., Weichenthal M., et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004, 53:1658-1664.
18. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
19. Clarke T.B., Weiser J.N. Intracellular sensors of extracellular bacteria. Immunol Rev 2011, 243:9-25.
20. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229-265.
21. Hugot J.P., Chamaillard M., Zouali H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
22. Ogura Y., Bonen D.K., Inohara N., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411(6837):603-606.
23. Economou M., Trikalinos T.A., Loizou K.T., Tsianos E., Ioannidis J.P. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004, 99:2393-2404.
24. Yamazaki K., Takazoe M., Tanaka T., Kazumori T., Nakamura Y. Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease. J Hum Genet 2002, 47:469-472.
25. Kugathasan S., Loizides A., Babusukumar U., et al. Comparative phenotypic and CARD15 mutational analysis among African American, Hispanic, and White children with Crohn's disease. Inflamm Bowel Dis 2005, 11:631-638.
26. Abraham C., Cho J.H. Functional consequences of NOD2 (CARD15) mutations. Inflamm Bowel Dis 2006, 12:641-650.
27. Watanabe T., Kitani A., Murray P.J., Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004, 5:800-808.
28. Noguchi E., Homma Y., Kang X., Netea M.G., Ma X. A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol 2009, 10:471-479.
29. Zhang F.R., Huang W., Chen S.M., et al. Genomewide association study of leprosy. N Engl J Med 2009, 361:2609-2618.
30. Henckaerts L., Vermeire S. NOD2/CARD15 disease associations other than Crohn's disease. Inflamm Bowel Dis 2007, 13:235-241.
31. Hampe J., Franke A., Rosenstiel P., et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007, 39:207-211.
32. Parkes M., Barrett J.C., Prescott N.J., et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007, 39:830-832.
33. Delgado M.A., Elmaoued R.A., Davis A.S., Kyei G., Deretic V. Toll-like receptors control autophagy. EMBO J 2008, 27:1110-1121.
34. Cooney R., Baker J., Brain O., et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010, 16:90-97.
35. Travassos L.H., Carneiro L.A., Ramjeet M., et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010, 11:55-62.
36. Kaser A., Blumberg R.S. Autophagy, microbial sensing, endoplasmic reticulum stress and epithelial function in inflammatory bowel disease. Gastroenterology 2011, 140:1738-1747.
37. Vermeire S., Rutgeerts P., Van Steen K., et al. Genome wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistasis. Gut 2004, 53:980-986.
38. Barmada M.M., Brant S.R., Nicolae D.L., et al. A genome scan in 260 inflammatory bowel disease-affected relative pairs. Inflamm Bowel Dis 2004, 10:513-520.
39. Hampe J., Schreiber S., Shaw S.H., et al. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet 1999, 64:808-816.
40. Kaser A., Lee A.H., Franke A., et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008, 134:743-756.
41. Duerr R.H., Taylor K.D., Brant S.R., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461-1463.
42. Cargill M., Schrodi S.J., Chang M., et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007, 80:273-290.
43. Burton P.R., Clayton D.G., Cardon L.R., et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007, 39:1329-1337.
44. Barrett J.C., Hansoul S., Nicolae D.L., et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008, 40:955-962.
45. Fisher S.A., Tremelling M., Anderson C.A., et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet 2008, 40:710-712.
46. Franke A., Balschun T., Karlsen T.H., et al. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 2008, 40:713-715.
47. Cua D.J., Tato C.M. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010, 10:479-489.
48. Takatori H., Kanno Y., Watford W.T., et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 2009, 206:35-41.
49. Cella M., Fuchs A., Vermi W., et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009, 457:722-725.
50. Crellin N.K., Trifari S., Kaplan C.D., Cupedo T., Spits H. Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+lineage distinct from conventional natural killer cells. J Exp Med 2010, 207:281-290.
51. Satoh-Takayama N., Lesjean-Pottier S., Vieira P., et al. IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46+ cell subsets from Id2-dependent precursors. J Exp Med 2010, 207:273-280.
52. Buonocore S., Ahern P.P., Uhlig H.H., et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 2010, 464:1371-1375.
53. Geremia A., Arancibia-Cárcamo C.V., Fleming M.P., et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 2011, 208:1127-1133.
54. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994, 12:227-257.
55. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517.
56. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 2002, 347:417-429.
57. Monteleone G., Trapasso F., Parrello T., et al. Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 1999, 163:143-147.
58. Monteleone G., Biancone L., Marasco R., et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997, 112:1169-1178.
59. Breese E., Braegger C.P., Corrigan C.J., Walker-Smith J.A., MacDonald T.T. Intereukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology 1993, 78:127-131.
60. Noguchi M., Hiwatashi N., Liu Z., Toyota T. Enhanced interferon-gamma production and B7-2 expression in isolated intestinal mononuclear cells from patients with Crohn's disease. J Gastroenterol 1995, 8:52-55. [Suppl.].
61. Camoglio L., Te Velde A.A., Tigges A.J., Das P.K., Van Deventer S.J. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis 1998, 4:285-290.
62. Heller F., Florian P., Bojarski C., et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005, 129:550-564.
63. Fuss I.J., Heller F., Boirivant M., et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004, 113:1490-1497.
64. Di Sabatino A., Biancheri P., Rovedatti L., Macdonald T.T., Corazza G.R. New pathogenic paradigms in inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:368-371.
65. Rovedatti L., Kudo T., Biancheri P., et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 2009, 58:1629-1636.
66. Vainer B., Nielsen O.H., Hendel J., Horn T., Kirman I. Colonic expression and synthesis of interleukin 13 and interleukin 15 in inflammatory bowel disease. Cytokine 2000, 12:1531-1536.
67. Kadivar K., Ruchelli E.D., Markowitz J.E., et al. Intestinal interleukin-13 in pediatric inflammatory bowel disease patients. Inflamm Bowel Dis 2004, 10:593-598.
68. Wilson M.S., Ramalingam T.R., Rivollier A., et al. Colitis and intestinal inflammation in IL10-/- mice results from IL-13Rα2-mediated attenuation of IL-13 activity. Gastroenterology 2011, 140:254-264.
69. Bernardo D., Vallejo-Díez S., Mann E.R., et al. IL-6 promotes immune responses in human ulcerative colitis and induces a skin-homing phenotype in the dendritic cells and T cells they stimulate. Eur J Immunol 2012, 42:1337-1353.
70. Zhou L., Ivanov I.I., Spolski R., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967-974.
71. Sarra M., Pallone F., Macdonald T.T., Monteleone G. IL-23/IL-17 axis in IBD. Inflamm Bowel Dis 2010, 16:1808-1813.
72. Harrington L.E., Hatton R.D., Mangan P.R., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
73. Annunziato F., Cosmi L., Santarlasci V., et al. Phenotypic and functional features of human Th17. J Exp Med 2007, 204:1849-1861.
74. Kobayashi T., Okamoto S., Hisamatsu T., et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 2008, 57:1682-1689.
75. Sugihara T., Kobori A., Imaeda H., et al. The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease. Clin Exp Immunol 2010, 160:386-393.
76. Fujino S., Andoh A., Bamba S., et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003, 52:65-70.
77. Monteleone G., Monteleone I., Fina D., et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 2005, 128:687-694.
78. Sarra M., Monteleone I., Stolfi C., et al. Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis 2010, 16:1332-1339.
79. Fina D., Sarra M., Fantini M.C., et al. Regulation of gut inflammation and Th17 cell response by interleukin-21. Gastroenterology 2008, 134:1038-1048.
80. O'Garra A., Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004, 10:801-805.
81. Valencia X., Stephens G., Goldbach-Mansky R., Wilson M., Shevach E.M., Lipsky P.E. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006, 108:253-261.
82. Fantini M.C., Becker C., Tubbe I., et al. Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut 2006, 55:671-680.
83. Singh B., Read S., Asseman C., et al. Control of intestinal inflammation by regulatory T cells. Immunol Rev 2001, 182:190-200.
84. Chamouard P., Monneaux F., Richert Z., et al. Diminution of circulating CD4+CD25 high T cells in naïve Crohn's disease. Dig Dis Sci 2009, 54:2084-2093.
85. Maul J., Loddenkemper C., Mundt P., et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005, 128:1868-1878.
86. Saruta M., Yu Q.T., Fleshner P.R., et al. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Clin Immunol 2007, 125:281-290.
87. Eastaff-Leung N., Mabarrack N., Barbour A., Cummins A., Barry S. Foxp3+ regulatory T cells Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol 2010, 30:80-89.
88. Monteleone G., Kumberova A., Croft N.M., McKenzie C., Steer H.W., MacDonald T.T. Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001, 108:601-609.
89. Fahlen L., Read S., Gorelik L., et al. T cells that cannot respond to TGF-β escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med 2005, 201:737-746.
90. Fantini M.C., Rizzo A., Fina D., et al. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology 2009, 136:1308-1316.
91. Lee Y.K., Mukasa R., Hatton R.D., Weaver C.T. Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol 2009, 21:274-280.
92. Pender S.L., Lionetti P., Murch S.H., Wathan N., MacDonald T.T. Proteolytic degradation of intestinal mucosal extracellular matrix after lamina propria T cell activation. Gut 1996, 39:284-290.
93. Di Sabatino A., Rovedatti L., Kaur R., et al. Targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits Th1 cytokine production and T-box transcription factor T-bet in inflammatory bowel disease. J Immunol 2009, 183:3454-3462.
94. Di Sabatino A., Battista N., Biancheri P., et al. The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. Mucosal Immunol 2011, 4:574-583.
95. Biancheri P., Di Sabatino A., Corazza G.R., Macdonald T.T. Proteases and the gut barrier. Cell Tissue Res 2013, 351:269-280.
96. Macdonald T.T., Biancheri P., Sarra M., Monteleone G. What's the next best cytokine target in IBD?. Inflamm Bowel Dis 2012, 18:2180-2189.
97. Ceponis P.J., Botelho F., Richards C.D., McKay D.M. Interleukins 4 and 13 increase intestinal epithelial permeability by a phosphatidylinositol 3-kinase pathway. Lack of evidence for STAT 6 involvement. J Biol Chem 2000, 275:29132-29137.
98. Prasad S., Mingrino R., Kaukinen K., et al. Inflammatory processed have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest 2005, 85:1139-1162.
99. Heller F., Fuss I.J., Nieuwenhuis E.E., Blumberg R.S., Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002, 17:629-638.
100. Awane M., Andres P.G., Li D.J., Reinecker H.C. NF-kappa B-inducing kinase is a common mediator of IL-17-, TNFalpha-, and IL-1beta-induced chemokine promoter activation in intestinal epithelial cells. J Immunol 1999, 162:5337-5344.
101. Kolls J.K., Linden A. IL-17 family members and inflammation. Immunity 2004, 21:467-476.
102. Hueber W., Sands B.E., Lewitzky S., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012, 61:1693-1700.
103. Macdonald T.T. Inside the microbial and immune labyrinth: totally gutted. Nat Med 2010, 16:1194-1195.
104. Iborra M., Beltrán B., Nos P. New knowledge in genetics and inflammatory bowel disease. Are there any practical applications?]. Gastroenterol Hepatol 2011, 34:591-598.
105. Hayter S.M., Cook M.C. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev 2012, 11:754-765.
106. Bernink J.H., Peters C.P., Munneke M., Te Velde A.A., Meijer S.L., Weijer K., et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol 2013, 14(3):221-229.